Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.56 |
| ▸ | CTSK | P43235 | 6/20 | 0.56 |
| ▸ | CTSL | P07711 | 5/20 | 0.56 |
| ▸ | CTSB | P07858 | 3/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.53 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.53 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.53 |
| ▸ | PPID | Q08752 | 1/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7536642 | 1.00 | CTSS (0.56) | CTSSCTSKCTSLCTSBSIRT2 | |
| SCHEMBL9068032 | 0.93 | CTSS (0.57) | CTSSCTSKCTSLCTSB | |
| SCHEMBL10790294 | 0.91 | CTSL (0.69) | CTSSCTSKCTSLCTSB | |
| SCHEMBL6661701 | 0.91 | CTSL (0.69) | CTSSCTSKCTSLCTSB | |
| SCHEMBL11659096 | 0.90 | CTSL (0.57) | CTSSCTSKCTSLCTSB | |
| SCHEMBL24130351 | 0.89 | CTSK (0.56) | CTSSCTSKCTSLCTSBSIRT2 | |
| SCHEMBL8245664 | 0.89 | CTSK (0.56) | CTSSCTSKCTSLCTSBSIRT2 | |
| SCHEMBL9807063 | 0.88 | CTSK (0.70) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL11513551 | 0.87 | BCHE (0.60) | CTSSCTSKCTSLCTSBSIRT2 | |
| SCHEMBL11513546 | 0.87 | BCHE (0.60) | CTSSCTSKCTSLCTSBSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592436-A4 | COMPOUNDS THAT BIND P2Y sb 2 /sb OR P2Y sb 1 /sb RECEPTORS | KIMBERLY CLARK CO (US) | 2009-09-02 | — | — | EP | claimed |
| US-7056889-B2 | Compounds that bind P2Y2 or P2Y1 receptors | KIMBERLY-CLARK, WORLDWIDE, INC. (US) | 2006-06-06 | — | — | US | claimed |
| EP-1592436-A2 | COMPOUNDS THAT BIND P2Y sb 2 /sb OR P2Y sb 1 /sb RECEPTORS | Kimberly-Clark Worldwide, Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004060907-A2 | COMPOUNDS THAT BIND P2Y2 OR P2Y1 RECEPTORS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2004-07-22 | — | — | WO | claimed |
| US-20040116339-A1 | Compounds that bind P2Y2 or P2Y1 receptors | KIMBERLY-CLARK WORLDWIDE, INC. | 2004-06-17 | — | — | US | claimed |
| US-20090306009-A1 | Modulation of the P2Y2 Receptor Pathway | P2-SCIENCE APS (DK) | 2009-12-10 | — | — | US | disclosed |
| EP-1592436-A4 | COMPOUNDS THAT BIND P2Y sb 2 /sb OR P2Y sb 1 /sb RECEPTORS | KIMBERLY CLARK CO (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-2036567-A2 | Modulation of the P2Y2 receptor pathway | P2-Science APS (DK) | 2009-03-18 | — | — | EP | disclosed |
| EP-1959968-A2 | MODULATION OF THE P2Y2 RECEPTOR PATHWAY | P2-Science APS (DK) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007065437-A2 | MODULATION OF THE P2Y2 RECEPTOR PATHWAY | P2-SCIENCE APS (DK) | 2007-06-14 | — | — | WO | disclosed |
| US-7056889-B2 | Compounds that bind P2Y2 or P2Y1 receptors | KIMBERLY-CLARK, WORLDWIDE, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1592436-A2 | COMPOUNDS THAT BIND P2Y sb 2 /sb OR P2Y sb 1 /sb RECEPTORS | Kimberly-Clark Worldwide, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004060907-A2 | COMPOUNDS THAT BIND P2Y2 OR P2Y1 RECEPTORS | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2004-07-22 | — | — | WO | disclosed |
| US-20040116339-A1 | Compounds that bind P2Y2 or P2Y1 receptors | KIMBERLY-CLARK WORLDWIDE, INC. | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306009-A1 | Modulation of the P2Y2 Receptor Pathway | P2RY2, P2RY1, P2RY11 | CTSS 4513/4885CTSK 4396/4885CTSL 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.